New drug VSA012 takes first step in human safety trial
NCT ID NCT06766929
First seen May 10, 2026 · Last updated May 25, 2026 · Updated 3 times
Summary
This early-stage study tests the safety of a new drug, VSA012, in 40 healthy adults. The drug targets the complement system, which is part of the body's immune defense, and may help treat diseases like PNH where this system is overactive. Participants receive a single dose of VSA012 or a placebo, and researchers monitor for side effects and how the drug moves through the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Peking University Third Hospital
Beijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.